Publications by authors named "Robert M L Orme"
Intensive Care Med
October 2019
Article Synopsis
- Myocardial dysfunction is prevalent in sepsis, but a study called the LeoPARDS trial found that the inodilator levosimendan does not improve organ dysfunction or reduce mortality in septic shock patients.
- The research measured cardiac biomarkers and inflammatory mediators in patients to assess the drug's effects, revealing no benefits in reducing the SOFA score or 28-day mortality rates.
- Specifically, patients with high NT-proBNP who received levosimendan showed worse SOFA scores compared to those on placebo, indicating that levosimendan added to standard care does not enhance outcomes in septic patients with cardiac dysfunction.
N Engl J Med
October 2016
Article Synopsis
- Levosimendan is a drug that may help patients with sepsis by improving organ function, and a clinical trial was conducted to test its effectiveness compared to a placebo.
- The study included 516 patients, with no significant differences found in mean organ dysfunction scores or 28-day mortality rates between the levosimendan and placebo groups.
- However, patients receiving levosimendan had a lower success rate in weaning off mechanical ventilation and experienced more cases of a specific heart rhythm issue (supraventricular tachyarrhythmia) compared to those receiving placebo.
